Regioselective production of sulfated polyphenols using human cytosolic sulfotransferase (SULT)-expressing *Escherichia coli* cells

Takehiko Shimohira[1,2], **Katsuhisa Kurogi**[1,2], **Takuyu Hashiguchi**[1,2], **Ming-Cheh Liu**[3], **Masahito Suiko**[1,2], and **Yoichi Sakakibara**[1,2,*]

[1]Department of Biochemistry and Applied Biosciences, University of Miyazaki, 1-1 Gakuenkibanadai-Nishi, Miyazaki 889-2192, Japan

[2]Interdisciplinary Graduate School of Agriculture and Engineering, University of Miyazaki, 1-1 Gakuenkibanadai-Nishi, Miyazaki 889-2192, Japan

[3]Department of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA

Abstract

Dietary polyphenols present in fruits and vegetables have been reported to manifest beneficial health effects on humans. Polyphenol metabolites including their sulfated derivatives have been shown to be biologically active. Primarily due to the difficulty in preparing regiospecific sulfated polyphenols for detailed investigations, the exact functions of sulfated polyphenols, however, remain unclear. The current study aimed to develop a procedure for the regioselective production of sulfated polyphenols using *E. coli* cells expressing human cytosolic sulfotransferases (SULTs). Two regioisomers of sulfated genistein were produced by *E. coli* cells expressing human SULT1A3, SULT1C4, or SULT1E1, and purified using Diaion HP20 resin, followed by high pressure liquid chromatography (HPLC). Structural analysis using mass spectrometry (MS) and nuclear magnetic resonance (NMR) revealed that *E. coli* cells expressing SULT1A3 preferentially produced genistein 4'-sulfate, whereas *E. coli* cells expressing SULT1C4 preferentially produced genistein 7-sulfate. To improve the bioproductivity, the effects of several factors including the concentrations of glucose and SO_4^{2-}, and growth temperature were investigated. The bioproduction procedure established in this study will be valuable for the production of regioselective sulfated polyphenols for use in future studies on their biological functions.

Keywords

Cytosolic sulfotransferase; regioselective sulfation; polyphenol metabolites; sulfated genistein; bioproduction

*Corresponding Author: Yoichi Sakakibara, Department of Biochemistry and Applied Biosciences, University of Miyazaki, 1-1 Gakuenkibanadai-Nishi, Miyazaki, Miyazaki, 889-2192, Japan. Tel/Fax: +81-985-58-7211, ysakaki@cc.miyazaki-u.ac.jp.

Introduction

Dietary polyphenols present in various fruits and vegetables have been reported to manifest beneficial health effects on humans (1, 2). These conclusions were mostly based on *in vitro* studies using aglycone or glycoside forms of flavonoids (3, 4). In human body, however, many phenolic compounds may be subjected to biotransformation via conjugation reactions such as sulfation and glucuronidation, (5, 6). Intriguingly, recent studies indicated that sulfated polyphenols may still be biologically active. For example, like unconjugated resveratrol, resveratrol 3-sulfate and resveratrol disulfate both were capable of inhibiting the *E. coli* LPS-induced release of TNF-α by macrophages (7). In another study, daidzein 7-sulfate was shown to affect transcriptional and anti-proliferative activities of estrogen receptor-β in cancer cells, whereas daidzein 4'-sulfate and daidzein 7, 4'-disulfate were inactive (8). While the biological activity of these polyphenol metabolites has been noted, the precise function of respective sulfated forms of flavonoids remains unclear due mostly to the difficulty in preparing regiospecific sulfated polyphenol compounds. Regioselective production of sulfated compounds by chemical synthesis is complicated and involves multiple reaction steps. On the other hand, enzymatic production, while allowing for regiospecifically producing sulfated polyphenols, is not suitable for their mass production. Recently, microbial bioconversion using genetically engineered bacteria, particularly *E. coli*, has been developed for the regioselective glucuronidation or methylation of polyphenol compounds (9, 10). Similar procedures, however, have not yet been developed for the production of sulfated polyphenols.

Sulfate conjugation is known to be involved in the biotransformation and elimination of xenobiotics such as drugs and some dietary compounds, and for the homeostasis of key endogenous compounds such as steroid/thyroid hormones, catecholamines, and bile acids (11-13). The cytosolic sulfotransferases (SULTs) catalyze the transfer of a sulfonate group from the sulfate donor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS), to various compounds containing hydroxyl and/or amino group(s) (14). In higher organisms, PAPS is synthesized in the cytosol by a bifunctional PAPS synthetase (PAPSS) with both the ATP sulfurylase and APS kinase activities (15-17). In bacteria, fungi, algae, and plants, these enzymatic activities are, however, associated with distinct enzymes encoded by separate genes (18, 19). In humans, 13 SULTs that fall into four major gene families (SULT1, SULT2, SULT4 and SULT6) have been identified (20, 21). Of the 13 human SULTs, the seven SULT1 family members, SULT1A1, SULT1A2, SULT1A3, SULT1B1, SULT1C2, SULT1C4 and SULT1E1, have been shown to be capable of catalyzing the sulfation of dietary polyphenols such as isoflavones (e.g., genistein, daidzein) and flavonols (e.g., quercetin, kaempherol) (22). Interestingly, the sulfation of polyphenols occurred in a regioselective manner and that the regiospecificity varied depending on the responsible SULT enzymes. For example, SULT1A3 catalyzes the 4'- sulfation of genistein and daidzein, whereas SULT1E1 catalyzes the sulfation at 7- and 4'-position of those polyphenols (23). A variety of regioisomers of sulfated polyphenols therefore may be produced in human body.

In this communication, we report the establishment of a procedure for the regioselective production of sulfated polyphenols using *E. coli* cells expressing different human SULTs. Genistein was chosen as a model polyphenol in this study because genistein has been shown to be regioselectively sulfated by human SULTs (23). To our knowledge, this is the first study using genetically engineered bacteria for the regioselective production of sulfated polyphenols.

Materials and Methods

Materials

Genistein was purchased from Wako Pure Chemical Industries (Osaka, Japan). Trifluoroacetic acid (TFA) and sulfatase (from *Helix pomatia*) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Isopropyl β-D-thiogalactopyranoside (IPTG) was a product of Takara Bio (Shiga, Japan). BL21 *Escherichia coli* host strain was from Stratagene (La Jolla, CA, USA). pGEX-2TK prokaryotic GST fusion vector was from GE Healthcare Biosciences (Amersham Place, Little Chalfont, England). M9 medium and LB medium were prepared as reported previously (24). All other chemicals were of the highest grade commercially available.

Bioconversion of Genistein using human SULT-expressing *E. coli* cells

By employing the reverse transcription-polymerase chain reaction technique, we had previously cloned the cDNAs encoding human SULT1A3 (Gene ID: NM_177552), SULT1C4 (Gene ID: NM_006588), and SULT1E1 (Gene ID: NM_005420) (22). These three human SULT cDNAs were individually ligated into the pGEX-2TK prokaryotic expression vector. pGEX-2TK vector harboring SULT1A3, SULT1C4, or SULT1E1 cDNA was transformed into competent *E. coli* BL21 cells. Transformed cells were grown to $OD_{600\ nm}$=0.6~1.0 in 200 mL LB medium containing 100 μg/mL of ampicillin, and the expression of the recombinant SULT enzyme was induced using 0.25 mM IPTG. Expression of respective SULT was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE was performed on 10% polyacrylamide gels based on Laemmli's method (25). Following a 9-hour induction at 24°C, the cells were collected by centrifugation and resuspended in 100 mL of M9 medium supplemented with 0.5 mM genistein, 5% dimethyl sulfoxide (DMSO), 50 mM glucose, 2 mM $MgSO_4$, 100 μg/mL ampicillin, and 0.25 mM IPTG, and the cell density was adjusted to $OD_{600\ nm} = 2.5\text{-}3.0$. This cell density was empirically chosen based on tolerance to potential toxicity of 5% DMSO needed to dissolve genistein to a 0.5 mM concentration and efficiency in the production of sulfated metabolite. The cell suspension thus prepared was incubated at 24°C or 37°C for 24 h. Afterwards, the cells were spun down and the supernatant was collected for use as described below.

Preparation of Sulfated Genistein

The cultured supernatant prepared as described above was fractionated using 20 mL Diaion HP20 resin (Nippon Rensui, Tokyo, Japan). After fractionation, the resin was washed with H_2O, and genistein and its metabolites were eluted using 100 mL methanol. Ten mL H_2O was added to the eluate, and the mixture was evaporated and the remaining residue was

lyophilized. The freeze-dried powder was dissolved in 2 mL DMSO, and the solubilized genistein and its metabolites were separated by HPLC using a Shimadzu (Kyoto, Japan) Prominence HPLC system fitted with a photodiode array detector (258 nm). A 5 μm Capcell PAK C18 MGII column (4.6 × 250 mm; SHISEIDO, Tokyo, Japan) maintained at 40°C was used, and a gradient elution using 0.05 % TFA in H_2O and methanol at a flow rate of 1 mL/min for 55 min was applied. The methanol concentrations used were as follows: 0% (0-5 min), 0-70% (5-40 min), 70-100% (40-45 min), 100% (45-50 min), 100-0% (50-55) min, and 0% (55-60min). The fractionated sample was evaporated. After evaporation, the sample was re-fractionated with 20 mL Diaion HP20 and eluted with methanol, and the eluate was again evaporated. The sample thus purified was dissolved in methanol and analyzed by mass spectrometer. For NMR analysis, the purified sample was dissolved in DMSO-d6 (Aldrich, Chicago, IL, USA).

Mass Spectrometry (MS) Analysis

Samples prepared as described above were analyzed using a Q-Exactive hybrid quadrupole-orbitrap mass spectrometer (Thermo Fisher scientific, Rockford, IL, USA) with a heated electrospray ionization source generated by direct infusion injection using a syringe pump. Data were acquired via Target-MS^2 scan. Typical mass spectrometric analysis conditions used were as follows: polarity, negative ionization mode; spray voltage 2.0 kV; sheath gas flow rate, 10; auxiliary gas, 0; sweep gas, 0; heated capillary temperature, 270°C. The resolution was set at 140,000, and the AGC target was 2E5. The maximum injection time was 100 ms, and the normalized collision energy was 20%. The raw data files were analyzed using the Qual browser software in Xcalibur (Thermo fisher scientific, Rockford, IL., USA).

NMR Analysis

The sample dissolved in DMSO-d6 was analyzed using a Bruker Advance 400 instrument (400 MHz, 9.4 T) (Bruker, Karlsruhe, Germany). The chemical shifts (δ) for proton were given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard. For the ^{1}H NMR experiment, 32 transients were acquired with a spectral width of 8000 Hz. All NMR data were processed using XWINNMR (Bruker, Karlsruhe, Germany). The chemical structures of two sulfated forms of genistein were determined based on the NMR data.

Quantitative Analysis of Sulfated Genistein

To quantitatively determine the portion of genistein that was present in sulfated form, the sample was treated with type H-1 sulfatase from *Helix pomatia*, and the sulfatase-treated sample was compared with untreated control with the same amount of unconjugated genistein. Treatment with sulfatase was performed according to the manufacturer's instructions with a slight modification. The reaction mixture, with a final volume of 100 μL, contained sulfatase (0.1 unit), fractionated genistein sulfate preparation, and 150 mM of Tris-HCl buffer (pH 8.0). Upon incubation for 4 hrs at 37°C, 50 μL of methanol was added and the mixture heated at 98°C for 3 minutes to stop the reaction. The heated sample was centrifuged at 1,5000 × g for 10 min, and the supernatant collected was analyzed by HPLC for unconjugated genistein, compared with a standard curve prepared using commercial genistein.

Results and Discussion

Production of Sulfated Genistein by *E. coli* Cells Expressing Human SULTs

In this study, genistein was chosen as a model compound for investigating the production of regiospelectively sulfated product(s) using *E. coli* BL21 cells expressing human SULT1A3, SULT1C4, or SULT1E1. A previous study demonstrated that SULT1A3 catalyzed exclusively 4'-sulfation of genistein, whereas SULT1E1 catalyzed both 4'-sulfation and 7-sulfation (23). In the case of SULT1C4, while it has been shown to display strong sulfating activity toward genistein, its regioselectivity in mediating the sulfation of genistein remained unclear (22). It is noted that three other human SULT1 enzymes, SULT1A1, SULT1A2, and SULT1B1, have also been reported to display sulfating activity toward genistein (22). Our preliminary screening revealed, however, that SULT1A1, SULT1A2, and SULT1B1 displayed low regioselectivity toward genistein (date not shown). The remaining human SULT1 enzyme, SULT1C2, on the other hand, has been reported to be incapable of sulfating genistein (22). *E. coli* BL21 cells transformed with pGEX-2TK-SULT1A3, SULT1C4, or SULT1E1 cDNA were incubated in LB medium and the expression of GST-SULT fusion protein was induced by 0.25 mM IPTG and confirmed by SDS-PAGE (Fig. 1). These recombinant SULTs were expressed in the highly soluble GST fusion protein form in order to avoid inclusion body formation in *E. coli* cells. The bioconversion of genistein using *E. coli* expressing human SULT1A3, SULT1C4, or SULT1E1 was performed as described in "Materials and Methods". Following a 24-hour incubation, the cell suspension was centrifuged, and the supernatant collected was subjected to HPLC analysis. As shown in Figure 2 (A), the aglycon form and two products (designated P1 and P2) derived from genistein were detected. Interestingly, the *E. coli* cells expressing GST-SULT1A3 preferentially produced P1, whereas *E. coli* cells expressing GST-SULT1C4 preferentially produced P2. For *E. coli* cells expressing GST-SULT1E1, approximately equal amounts of P1 and P2 were detected (Fig. 2A). Both P1 and P2 were hydrolyzed to became parent genistein by sulfatase (date not shown), indicating their identity being (sulfated) metabolites of genistein. It is interesting to point out that in the aforementioned bioconversion experiments, sulfated products of genistein were found to accumulate extracellularly, but not intracellularly. Previous studies have revealed that *E. coli* cells may express 37 multidrug resistance transporters, belonging to resistance-nodulation-division (RND), major facilitator superfamily (MSF), ATP binding cassettle (ABC), and small multidrug resistance (SMR) families, that function to eliminate various xenobiotics and drugs, as well as organic anion compounds (26-29). It is possible that sulfated products of genistein, which are also organic anion compounds, might have been eliminated extracellularly by these transporters. Moreover, once out of the cells, sulfated genistein may be unable to cross the cell membrane of *E. coli* cells due to the negative charged sulfate group. As a result, sulfated products generated by SULT-expressing *E. coli* cells all accumulated in the extracellular fraction.

Structural Determination of Sulfated Genistein Produced by *E. coli* Cells Expressing Human SULT

To clarify their chemical structure, P1 and P2, purified as described in "Materials and Methods", were subjected to the MS and NMR analyses. Negative ion mode full-scan mass spectrometry showed that the highest relative abundance for both P1 and P2 was at m/z

349.00, which corresponded to the theoretical monoisotopic mass for the $[M-H]^-$ ion of mono-sulfated genistein (genistein 7-sulfate or genistein 4'-sulfate). As shown in Fig 2 (B, C), further selected ion monitoring of each parent ion and the subsequent high-energy collision dissociation fragmentation of the parent ions produced authentic genistein lacking one SO_3^- group (m/z 79.96) at m/z 269.04. These results indicated that P1 and P2 were indeed mono-sulfated genistein. To further determine the chemical structure of P1 and P2, ^{1}H NMR analysis was performed (Fig. 3A, 3B). The ^{1}H NMR spectra (400MHz, DMSO-d6) of genistein and its sulfated products, P1 and P2, obtained were: genistein: δ 8.33s (H2), 7.37d (J = 8.6 Hz, H2' and H6'), 6.81d (J = 8.7 Hz, H3' and H5'), 6.38d (J = 2.1 Hz, H8), 6.23d (J = 2.1 Hz, H6); P1 (genistein 4'-sulfate): δ 8.4s (H2), 7.46d (J = 8.6 Hz, H2' and H6'), 7.22d (J = 8.6 Hz, H3' and H5'), 6.4d (J = 2.0 Hz, H8), 6.24d (J = 2.0 Hz, H6); P2 (genistein 7-sulfate): δ 8.42s (H2), 7.40d (J = 8.6 Hz, H2' and H6'), 6.9d (J = 2.1 Hz, H8), 6.82d (J = 8.6 Hz, H3' and H5'), 6.63d (J = 8.6 Hz, H6). Compared with that of genistein, the ^{1}H NMR spectrum of P1 showed a lower field shift (δ −0.41) at H3' and H5', indicating that the hydroxyl group at 4' position of genistein was substituted by a sulfate group. On the other hand, the ^{1}H NMR spectrum of P2 showed a lower shift (H6: δ −0.4, H8: δ −0.5) at H6 and H8, indicating that the hydroxyl group at 7 position of genistein was substituted by a sulfate group. These ^{1}H NMR spectra were in agreement with those of genistein 4'-sulfate and genistein 7-sulfate prepared by organic synthesis (23). Based on these results, it can be concluded that P1 and P2 were, respectively, genistein 4'-sulfate and genistein 7-sulfate. *E. coli* cells expressing GST-SULT1A3 therefore preferentially produced genistein 4'-sulfate, whereas *E. coli* cells expressing GST-SULT1C4 preferentially produced genistein 7-sulfate.

Effect of Glucose, Inorganic Sulfate, and Temperature on Microbial Production of Sulfated Genistein

An important issue is whether the culture condition such as the concentration of glucose or inorganic sulfate (SO_4^{2-}) and temperature may affect the production of sulfated genistein by *E. coli* cells expressing human SULT. It is known that ATP and SO_4^{2-} are essential precursors for the synthesis of the sulfonate donor, PAPS (5-7). We therefore decided to investigate the production of sulfated genistein by GST-SULT1C4-expressing *E. coli* cells incubated in media containing different concentrations of glucose and $MgSO_4$. As shown in Fig. 4 (A, B), in the medium without glucose or $MgSO_4$ the production of genistein sulfate was markedly low. In medium supplemented with glucose, however, the production of genistein 7-sulfate was substantially enhanced, with the optimum concentration of glucose being 50 mM. At elevated concentrations of glucose (100 - 400 mM), the production of genistein 7-sulfate was suppressed. In regard to the effects of inorganic sulfate, the production of genistein 7-sulfate was quite efficient at $MgSO_4$ concentrations above 1 mM. The effects of glucose or $MgSO_4$ on the production of sulfated genistein by GST-SULT1A3- or GST-SULT1E-expressing *E. coli* cells was examined and similar results were obtained (date not shown). These results, therefore, indicated that both glucose and SO_4^{2-} are essential factors for the production of sulfated genistein by SULT-expressing *E. coli* cells. Another factor that may affect the production of sulfated genistein is the temperature at which the *E. coli* culture is maintained. To find out whether this is the case, the production of sulfated genistein by GST-SULT-expressing *E. coli* cells at different incubation

temperatures (18°C, 24°C, 30°C or 37°C) was examined. As shown in Fig. 5 (A-C), all GST-SULT-expressing *E. coli* cell cultures showed low productivity on production of each regioselective sulfated genistein at 18 °C. Also, there was not much difference in the production of genistein 4'-sulfate by GST-SULT1A3-expressing *E. coli* cells incubated at different temperatures ranging 24°C to 37°C (Fig. 5A). In contrast, there was a significant temperature effect on the production of genistein 7-sulfate by GST-SULT1C4-expressing *E. coli* cells. The production of genistein 7-sulfate by GST-SULT1C4-expressing *E. coli* cells increased in a temperature-dependent manner in the temperature range from 18°C to 37°C (Fig. 5B). These results indicated that incubation temperature was also an important factor that may affect the production of sulfated compound by GST-SULT-expressing *E. coli* cells. Taken together, the above-mentioned results indicated that the M9 medium containing 50 mM glucose and 1 mM (or higher concentration of) $MgSO_4$ appeared to be the optimal for the regioselective production of genistein sulfate using this bioconversion method. In addition, using *E. coli* cells expressing GST-SULT1C4 at 37°C provided the highest efficiency in the regioselective production of genistein 7-sulfate. Similarly, the production of genistein 4'-sulfate was most efficient when GST-SULT1E1-expressing *E. coli* cells were incubated at 37°C (Fig. 5C). GST-SULT1E1-expressing *E. coli* cells however, exhibited low regioselctivity in the production of genistein sulfate. Therefore it may be better to use GST-SULT1A3-expressing *E. coli* cells for the selective production of genistein 4'-sulfate.

To summarize, we developed in the current study a bioconversion procedure for the regioselective production of sulfated genistein using *E. coli* expressing different human SULTs. Glucose, SO_4^{2-}, and incubation temperature were shown to be key factors that affected the efficiency of the production. The procedure developed may also be used for the regioselective production of other polyphenols (Shimohira et al., unpublished data). In recent years, it has been an interesting issue regarding the physiological function of phase II metabolites of polyphenols, as well as other dietary xenobiotics (23, 30). The regioselective production procedure established in this study will allow for large scale production of sulfated derivatives of polyphenols and other compounds for use in the functional studies in order to reveal in detail their physiological implications.

Acknowledgment

Reference

1. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, Griel AE, Etherton TD. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med. 2002; 113:71S–88S. [PubMed: 12566142]

2. Ullah MF, Khan MW. Food as medicine: potential therapeutic tendencies of plant derived polyphenolic compounds. Asian. Pac. J. Cancer. Prev. 2008; 9:187–195. [PubMed: 18712957]

3. García-Lafuente A, Guillamón E, Villares A, Rostagno MA, Martínez JA. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm. Res. 2009; 58:537–552. [PubMed: 19381780]

4. Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: chemistry, bioavailability and effects on health. Nat. Prod. Rep. 2009; 26:1001–1043. [PubMed: 19636448]

5. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 2004; 79:727–747. [PubMed: 15113710]

6. Yang CS, Sang S, Lambert JD, Lee MJ. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol. Nutr. Food. Res. 2008; 52:S139–S151. [PubMed: 18551457]

7. Walker J, Schueller K, Schaefer LM, Pignitter M, Esefelder L, Somoza V. Resveratrol and its metabolites inhibit pro-inflammatory effects of lipopolysaccharides in U-937 macrophages in plasma-representative concentrations. Food Funct. 2014; 5:74–84. [PubMed: 24257684]

8. Totta P, Acconcia F, Virgili F, Cassidy A, Weinberg PD, Rimbach G, Marino M. Daidzein-sulfate metabolites affect transcriptional and antiproliferative activities of estrogen receptor-beta in cultured human cancer cells. J. Nutr. 2005; 135:2687–2693. [PubMed: 16251631]

9. Kim SY, Lee HR, Park KS, Kim BG, Ahn JH. Metabolic engineering of *Escherichia coli* for the biosynthesis of flavonoid-O-glucuronides and flavonoid-O-galactoside. Appl. Microbiol. Biotechnol. 2015; 99:2233–2242. [PubMed: 25515812]

10. Kim MJ, Kim BG, Ahn JH. Biosynthesis of bioactive O-methylated flavonoids in *Escherichia coli*. Appl. Microbiol. Biot. 2013; 97:7195–7720.

11. Falany CN. Enzymology of human cytosolic sulfotransferases. FASEB J. 1997; 11:206–216. [PubMed: 9068609]

12. Hemmerich S, Verdugo D, Rath VL. Strategies for drug discovery by targeting sulfation pathways. Drug. Discov. Today. 2004; 9:967–975. [PubMed: 15539140]

13. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, McManus ME. Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci. 2006; 90:5–22. [PubMed: 16322073]

14. Lipmann F. Biological sulfate activation and transfer. Science. 1958; 128:575–580. [PubMed: 13580219]

15. Robbins PW, Lipmann F. Separation of the two enzymatic phases in active sulfate synthesis. J. Biol. Chem. 1958; 233:681–685. [PubMed: 13575436]

16. Robbins PW, Lipmann F. Enzymatic synthesis of adenosine-5'-phosphosulfate. J. Biol. Chem. 1958; 233:686–690. [PubMed: 13575437]

17. Li H, Deyrup A, Mensch JR Jr. Domowicz M, Konstantinidis AK, Schwartz NB. The isolation and characterization of cDNA encoding the mouse bifunctional ATP sulfurylase-adenosine 5'-phosphosulfate kinase. J. Biol. Chem. 1995; 270:29453–29459. [PubMed: 7493984]

18. Leyh TS. The physical biochemistry and molecular genetics of sulfate activation. Crit. Rev. Biochem. Mol. Biol. 1993; 28:515–542. [PubMed: 8299360]

19. Thomas D, Surdin-Kerjan Y. Metabolism of sulfur amino acids in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 1997; 61:503–532. [PubMed: 9409150]

20. Blanchard RL, Freimuth RR, Buck J, Weinshilboum RM, Coughtrie MWH. A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics. 2004; 14:199–211. [PubMed: 15167709]

21. Freimuth RR, Wiepert M, Chute CG, Wieben ED, Weinshilboum RM. Human cytosolic sulfotransferase database mining: identification of seven novel genes and pseudogenes. Pharmacogenomics. J. 2004; 4:54–65. [PubMed: 14676822]

22. Pai TG, Suiko M, Sakakibara Y, Liu MC. Sulfation of flavonoids and other phenolic dietary compounds by the human cytosolic sulfotransferases. Biochem. Biophys. Res. Commun. 2001; 5:1175–1179.

23. Nakano H, Ogura K, Takahashi E, Harada T, Nishiyama T, Muro K, Hiratsuka A, Kadota S, Watabe T. Regioselective monosulfation and disulfation of the phytoestrogens daidzein and genistein by human liver sulfotransferases. Drug Metab Pharmacokinet. 2004; 19:216–226. [PubMed: 15499189]

24. Sambrook, J., Fritsch, EF., Maniatis, T. Molecular cloning: a laboratory manual. 2nd. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, N.Y: 1989.

25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227:680–685. [PubMed: 5432063]

26. Rouch DA, Cram DS, DiBerardino D, Littlejohn TG, Skurray RA. Efflux-mediated antiseptic resistance gene qacA from *Staphylococcus aureus*: common ancestry with tetracycline- and sugar-transport proteins. Mol. Microbiol. 1990; 4:2051–2062. [PubMed: 2089219]

27. Wilmut I, Beaujean N, Sousa PA, Dinnyes A, King TJ, Paterson LA, Wells DN, Young LE. Somatic cell nuclear transfer. Nature. 2002; 419:583–586. [PubMed: 12374931]

28. McMurry L, Petrucci RE Jr. Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in *Escherichia coli*. Proc. Natl. Acad. Sci. U. S. A. 1980; 77:3974–3977. [PubMed: 7001450]

29. Poole K, Krebes K, McNally C, Neshat S. Multiple antibiotic resistance in *Pseudomonas aeruginosa*: evidence for involvement of an efflux operon. J. Bacteriol. 1993; 175:7363–7372. [PubMed: 8226684]

30. Yamazaki S, Sakakibara H, Takemura H, Yasuda M, Shimoi K. Quercetin-3-O-glucronide inhibits noradrenaline binding to α2-adrenergic receptor, thus suppressing DNA damage induced by treatment with 4-hydroxyestradiol and noradrenaline in MCF-10A cells. J. Steroid. Biochem. Mol. Biol. 2014; 143:122–129. [PubMed: 24607809]

Figure 1. Expression of GST-SULT in *E. coli* BL21 cells

E. coli BL21 cells were transformed with pGEX-2TK or pGEX-2TK harboring cDNA encoding human SULT, grown to 0.4 OD$_{600\ nm}$, and induced with IPTG for the expression of GST-SULT (see Materials and Methods). Recombinant GST-SULT expression was verified by SDS-PAGE. Lane M, molecular maker; Lane 1, Mock *E. coli* BL21 cells; Lane 2, *E. coli* BL21 cells expressing GST-SULT1A3; Lane 3, *E. coli* BL21 cells expressing GST-SULT1C4; Lane 4, *E. coli* BL21 cells expressing GST-SULT1E1.

Figure 2. HPLC analyses of spent *E. coli* M9 media and MS/MS spectra of purified sulfated products (P1 and P2)

(A) Medium samples were analyzed by HPLC equipped a photodiode array detector (258 nm) and a C18 reverse-phase column. The bioconversion of genistein was performed for 24 h at 24°C using *E. coli* cells expressing GST-SULT as described in Materials and methods. (a) Genistein; (b) Spent medium (M9) of *E. coli* BL21 cells transformed with empty pGEX-2TK vector (Mock); (c) Spent medium of *E. coli* BL21 cells expressing GST-SULT1A3; (d) Spent medium of *E. coli* BL21 cells expressing GST-SULT1C4; (e) Spent medium of *E. coli* BL21 cells expressing GST-SULT1E1. Genistein (f) and its metabolic products, P1 and P2, were indicated in each panel. (B) MS/MS spectrum of P1; (C) MS/MS spectrum of P2. MS/MS data were obtained from the 349.00 m/z ion as the precursor for high energy collisional dissociation.

Figure 3. Comparison of ^{1}H NMR spectra of genistein and its sulfated products (P1; genistein 4'-sulfate, P2; geniste 7-sulfate)

(A) Chemical structure of genistein. (B) ^{1}H NMR spectra of P1, P2, and genistein. NMR was performed as describe in Materials and Methods. The signals were assigned based on a previous report (23). Arrows indicate assigned positions of protons.

Figure 4. Effects of glucose and SO_4^{2-} on the production of sulfated genistein by *E. coli* BL21 cells expressing GST-SULT1C4

(A) Effect of the concentration of glucose (0, 25, 50, 100, 200 or 400 mM) on the production of genistein 7-sulfate by *E. coli* BL21 cells expressing GST-SULT1C4. The bioconversion of genistein was performed for 24 h at 24°C in the presence of 500 μM genistein, different concentrations of glucose, and 2 mM $MgSO_4$ as described in Materials and methods. (B) Effect of the concentration of SO_4^{2-} (0, 0.25, 0.5, 1, 2, or 4 mM) on the production of genistein 7-sulfate by *E. coli* BL21 cells expressing GST-SULT1C4. The bioconversion of genistein was performed for 24 h at 24°C in the presence of 500 μM genistein, 50 mM glucose, and different concentrations of $MgSO_4$ as described in Materials and methods.

Figure 5. Effect of temperature on microbial production of sulfated genistein

Effect of temperature (18°C, 24°C, 30°C or 37°C) on the production of sulfated genistein by *E. coli* BL21 cells expressing GST-SULT. (A) Spent medium of *E. coli* BL21 cells expressing GST-SULT1A3; (B) Spent medium of *E. coli* BL21 cells expressing GST-SULT1C4; (C) Spent medium of *E. coli* BL21 cells expressing GST-SULT1E1. Quantitative analysis of sulfated genistein was performed as described in Materials and Methods. Data shown represent means ± SD derived from three determinations.

Figure 6. Regioselective production of sulfated genistein by *E. coli* BL21 cells expressing human GST-SULT

The figure shows that *E. coli* BL21 cells expressing GST-SULT1A3 produces preferentially genistein 4'-sulfate; whereas *E. coli* BL21 cells expressing GST-SULT1C4 produces preferentially genistein 7-sulfate. *E. coli* BL21 cells expressing hSULT1E1, on the other hand, displayed low regioselectivity on sulfation of genistein. The bioproduction method developed in this study is thus useful for selectively producing regiospecific sulfated polyphenols.